S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Roku stock and the mother of all entry opportunities
The perfect AI stock under $10 (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The perfect AI stock under $10 (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Roku stock and the mother of all entry opportunities
The perfect AI stock under $10 (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The perfect AI stock under $10 (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Roku stock and the mother of all entry opportunities
The perfect AI stock under $10 (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The perfect AI stock under $10 (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Roku stock and the mother of all entry opportunities
The perfect AI stock under $10 (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The perfect AI stock under $10 (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

Guardant Health (GH) Stock Price, News & Analysis

$22.27
-0.39 (-1.72%)
(As of 02/22/2024 ET)
Today's Range
$21.94
$22.81
50-Day Range
$21.29
$28.75
52-Week Range
$20.67
$41.06
Volume
1.75 million shs
Average Volume
1.52 million shs
Market Capitalization
$2.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.75

Guardant Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
109.9% Upside
$46.75 Price Target
Short Interest
Healthy
4.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
0.45mentions of Guardant Health in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$155,580 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.58) to ($3.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.32 out of 5 stars

Medical Sector

120th out of 934 stocks

Medical Laboratories Industry

6th out of 21 stocks


GH stock logo

About Guardant Health Stock (NASDAQ:GH)

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

GH Stock Price History

GH Stock News Headlines

AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Here's what to expect from Guardant Health's earnings
Guardant Health Q4 2023 Earnings Preview
We Could Be Less Than 3 Months Out from an AI Superevent
According to one of the world’s top AI scientists, there’s a major event coming as soon as three months from today that could cause expensive tech stocks like Microsoft, Google, and NVIDIA to double or triple in price in the months ahead… but whatever you do, don’t go all in on big tech before you have all the details.
Guardant Health Inc (GH)
Baillie Gifford Acquires New Stake in Guardant Health Inc
BTIG Keeps Their Buy Rating on Guardant Health (GH)
See More Headlines
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
2/22/2024
Next Earnings (Confirmed)
2/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Employees
1,793
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$46.75
High Stock Price Target
$65.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+109.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-654,590,000.00
Pretax Margin
-80.35%

Debt

Sales & Book Value

Annual Sales
$535.79 million
Book Value
$0.59 per share

Miscellaneous

Free Float
110,676,000
Market Cap
$2.63 billion
Optionable
Not Optionable
Beta
0.99
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Helmy Eltoukhy Ph.D. (Age 45)
    Co-Founder, Co-CEO & Chairman
    Comp: $11.63k
  • Dr. AmirAli Talasaz Ph.D. (Age 45)
    Co-CEO & Director
    Comp: $11.18k
  • Mr. Michael Bell (Age 55)
    Chief Financial Officer
    Comp: $630.99k
  • Mr. John G. Saia (Age 51)
    Chief Legal Officer & Corporate Secretary
    Comp: $627.18k
  • Dr. Craig Eagle M.D. (Age 57)
    Chief Medical Officer
    Comp: $649.13k
  • Mr. Christopher Freeman (Age 50)
    Chief Commercial Officer
    Comp: $630.39k
  • Ms. Darya Chudova
    Chief Technology Officer
  • Mr. Kumud KaliaMr. Kumud Kalia (Age 58)
    Chief Information Officer
  • Ms. Jennifer Higgins
    Vice President of Public Affairs
  • Ms. Terilyn Juarez Monroe (Age 57)
    Chief People Officer














GH Stock Analysis - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GH shares.
View GH analyst ratings
or view top-rated stocks.

What is Guardant Health's stock price target for 2024?

15 Wall Street research analysts have issued 12 month price targets for Guardant Health's shares. Their GH share price targets range from $27.00 to $65.00. On average, they expect the company's stock price to reach $46.75 in the next year. This suggests a possible upside of 109.9% from the stock's current price.
View analysts price targets for GH
or view top-rated stocks among Wall Street analysts.

How have GH shares performed in 2024?

Guardant Health's stock was trading at $27.05 on January 1st, 2024. Since then, GH shares have decreased by 17.7% and is now trading at $22.27.
View the best growth stocks for 2024 here
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.58. The company earned $137.15 million during the quarter, compared to analysts' expectations of $129.44 million. Guardant Health had a negative trailing twelve-month return on equity of 322.25% and a negative net margin of 80.69%. The company's revenue for the quarter was up 25.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.25) EPS.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $655.0 million-$670.0 million, compared to the consensus revenue estimate of $669.4 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.43%), Baillie Gifford & Co. (5.24%), Capital International Investors (3.39%), Eventide Asset Management LLC (3.30%), FIL Ltd (1.67%) and Price T Rowe Associates Inc. MD (1.54%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Meghan V Joyce, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends
.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GH) was last updated on 2/23/2024 by MarketBeat.com Staff